Targeting PIK3CA Mutations in HR+/HER2- Breast Cancer: New Insights from ReDiscover

Host: Charles Turck, PharmD, BCPS, BCCCP <br> Guest: Sarah Sammons, MD <br> <p>About 40 percent of patients with metastatic HR+/HER2- breast cancer have an activating mutation in the <i>PIK3CA</i> gene,^1,2 which plays a key role not only in tumor growth, but also in driving resistance to endocrine therapy.^3-5 And while there are several FDA-approved PI3K pathway-targeted agents for patients with <i>PIK3CA</i> tumor mutations,^6-8 they come with challenges, like modest efficacy and on-pathway effects.^9-12 Given this unmet need, the ReDiscover trial evaluated the investigational agent RLY-2608 in combination with fulvestrant in in patients with PIK3CA-mutated HR+/HER2- aBC previously treated with a CDK4/6 inhibitor.¹³<strong> </strong>Joining Dr. Charles Turck to share updated safety and efficacy data from the trial is Dr. Sarah Sammons, a Senior Physician at the Dana-Farber Cancer Institute and an Assistant Professor ...